The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Lisaftoclax plus azacitidine for treatment-naïve or venetoclax-exposed myeloid malignancies
Shaun Fleming, MBBS, FRACP, FRCPA, Alfred Hospital, Melbourne, Australia, discusses early-phase data of lisaftoclax in combination with azacitidine for patients with treatment-naïve or venetoclax-exposed myeloid malignancies. Dr Fleming notes that this novel BCL2 inhibitor offers a potential alternative for patients who have received prior BCL2 inhibition, including those exposed to venetoclax.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that this was interesting data looking at the use of a novel BCL2 inhibitor in patients who have had prior BCL2 inhibition as part of their treatment for a myeloid malignancy. This is a really important group of unmet need because we now have patients who were treated with venetoclax and azacitidine routinely and this study demonstrated that we have appreciable response rates in patients being treated with lisaftoclax, which I’m not very good at pronouncing, despite the fact that they had prior venetoclax exposure...
I think that this was interesting data looking at the use of a novel BCL2 inhibitor in patients who have had prior BCL2 inhibition as part of their treatment for a myeloid malignancy. This is a really important group of unmet need because we now have patients who were treated with venetoclax and azacitidine routinely and this study demonstrated that we have appreciable response rates in patients being treated with lisaftoclax, which I’m not very good at pronouncing, despite the fact that they had prior venetoclax exposure. And so this gives us another option that we can potentially consider as we get more mature data and hopefully this agent does eventually become available in a more general approach.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
